Post Profile






Adding Modified Herpes Virus to Immunotherapy Shows Promise for Treating Advanced Melanoma

In a two-year study at UCLA, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug pembrolizumab with a herpes virus called talimogene laherpareovec, or T-VEC. Researchers led by Dr. Antoni Ribas found that the treatment's side effects were manageable, and comparable to side effects for people who took either pembrolizumab or T-VEC as a standalone treatment.
read more

share

Related Posts


After UCLA-Led Study, Combo Drug Therapy Approved by FDA to Treat Advanced Melanoma

Health : Newswise Medical News

FDA today approved a new therapy that combines vemurafenib (Zelboraf), a drug used to treat melanoma, with cobimetinib (Cotellic). Study conducted at UCLA and other sites internationally showed significantly improved response rates ...

Combo Immunotherapy for Advanced Melanoma: Two Therapies may be Better Than One

Health : Newswise Medical News

A new metastatic melanoma study suggests that a combination of two immunotherapies may be better than one: One treatment uses a patient's own T cells modified in the lab to more powerfully recognize and attack tumors; The other trea...

Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report at the ESMO Asia 2016 Congress in Singapo...

Medical News Today: Genetically modified herpes virus shows promise against melanoma

Health : Medical News Today

In a phase 3 trial, researchers showed how a genetically modified herpes virus halted disease progression in patients with advanced melanoma - the deadliest form of skin cancer.

UCLA Researchers Combine Benefits of Immunotherapy and Cancer-Targeted Treatment in Triple Combo Drug for Melanoma

Health : Newswise Medical News

Results of a new study by UCLA researchers has found that a groundbreaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor +...

Comments


Copyright © 2016 Regator, LLC